PHIO Stock — Phio Pharmaceuticals Corp

Phio Pharmaceuticals Corp (PHIO)

Updated October 16, 2026.

PHIO is a Stock. Total return is -100.0% over the past 14.4 years, 720.9 points behind SPY at 620.9%.

Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company developing immuno-oncology therapeutics, including PH-762 and PH-894 compounds designed to modulate immune response in cancer treatment. The company does not currently distribute to shareholders. Phio Pharmaceuticals appeals to investors with high risk tolerance seeking exposure to early-stage drug development rather than current income.

PHIO performance versus SPY

Price and return data through 2026-10-16.

Total return is -100.0% over the past 14.4 years, 720.9 points behind SPY at 620.9%. Over the past year its total return — price change plus distributions reinvested — is -58.9%. Its deepest 1-year drawdown was 60.4%.

PHIO key facts

Asset type

Stock

Asset class

Equity

Inception date

05/10/2012

Distribution frequency

None

Last close

$0.87 (as of 2026-10-16)

Market cap

$10,119,786

Average volume

91130.0

Payment date

01/15/2020

Beta

0.841

Payout ratio

0.0%

Forward P/E

0.3064

EPS

$-1.29

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

PHIO risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 60.4%.

Who may consider PHIO — and who may not

It is a weaker fit for investors who need monthly cash flow (PHIO does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on PHIO

• All tickers starting with P

Tagged: Healthcare.

Frequently asked questions